Company intelligence / Profile preview

AccuBio

Ownership: Private
Employees: ~100
Development stage: Commercial

Overview

Offers over-the-counter and professional-use rapid diagnostic tests with CE marking. Products are used in hospitals/labs/physician offices/home use across more than fifty countries. The company has invested heavily in automation to increase production capacity to up to two million lateral flow tests per week at its UK site. Recent expansion includes acquisition of Omega Diagnostics’ facility and product lines such as VISITECT® CD4 Advanced Disease test for HIV management.

Therapeutic areas: PulmonologyInfectious DiseasesOtherCardiovascularWomen's Health
Modalities: Diagnostic deviceLateral flow assayPCR-based diagnosticsFISH probe-based diagnostics
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on AccuBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AccuBio.

Explore the full profile